The companies clash over survival curve similarities – and differences.
ApexOnco Front Page
Recent articles
Petosemtamab's phase 2 data in this setting should come by the year end.
The company reckons its immunotherapy could improve on Keytruda.
Satri-cel is filed for gastric cancer approval in China.
First-in-human studies include a new pan-KRAS inhibitor and CDK2/4 degrader.
“We need all the capital we can get our hands on," the company states.
Astra/Daiichi have trumped Gilead’s Trodelvy with a lung cancer approval.
Zidesamtinib is having a hard time catching up with Ibtrozi's line-agnostic approval.
